Spots Global Cancer Trial Database for secondary myelodysplastic syndromes
Every month we try and update this database with for secondary myelodysplastic syndromes cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Infusion of Off-the-Shelf Expanded Cord Blood Cells to Augment Cord Blood Transplant in Patients With Hematologic Malignancies | NCT01175785 | Accelerated Pha... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Childhood Acute... Childhood Acute... Childhood Chron... Childhood Myelo... Chronic Phase C... de Novo Myelody... Previously Trea... Refractory Anem... Refractory Anem... Refractory Anem... Relapsing Chron... Secondary Myelo... | umbilical cord ... fludarabine pho... cyclophosphamid... ex vivo-expande... total-body irra... cyclosporine mycophenolate m... laboratory biom... | 6 Months - 45 Years | Nohla Therapeutics, Inc. | |
| Bryostatin 1 in Treating Patients With Myelodysplastic Syndrome | NCT00003171 | Leukemia Myelodysplastic... | bryostatin 1 | 18 Years - | Barbara Ann Karmanos Cancer Institute | |
| Azacitidine Plus Amifostine in Treating Patients With Myelodysplastic Syndrome | NCT00005598 | Myelodysplastic... | amifostine trih... azacitidine | 18 Years - | University of Michigan Rogel Cancer Center | |
| Combination Chemotherapy in Treating Older Patients With Acute Myeloid Leukemia | NCT00003602 | Leukemia Myelodysplastic... | cytarabine etoposide idarubicin mitoxantrone hy... | 55 Years - | National Cancer Institute (NCI) | |
| Cyclophosphamide and Busulfan Followed by Donor Stem Cell Transplant in Treating Patients With Myelofibrosis, Acute Myeloid Leukemia, or Myelodysplastic Syndrome | NCT00445744 | Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Childhood Acute... Childhood Myelo... de Novo Myelody... Essential Throm... Myelodysplastic... Polycythemia Ve... Previously Trea... Primary Myelofi... Recurrent Adult... Recurrent Child... Secondary Acute... Secondary Myelo... Secondary Myelo... Untreated Adult... Untreated Child... | cyclophosphamid... busulfan tacrolimus methotrexate cytogenetic ana... flow cytometry pharmacological... pharmacogenomic... peripheral bloo... allogeneic hema... | - 65 Years | Fred Hutchinson Cancer Center | |
| Combination Chemotherapy Followed By Peripheral Stem Cell Transplantation or Isotretinoin in Treating Patients With Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Acute Lymphocytic Leukemia | NCT00003619 | Chronic Myelopr... Leukemia Myelodysplastic... Thrombocytopeni... | filgrastim vitamin E busulfan cytarabine etoposide fludarabine pho... isotretinoin topotecan hydro... bone marrow abl... peripheral bloo... | 19 Years - 90 Years | National Cancer Institute (NCI) | |
| Sunitinib in Treating Patients With Myelodysplastic Syndromes or Chronic Myelomonocytic Leukemia | NCT00451048 | Chronic Myelomo... de Novo Myelody... Myelodysplastic... Secondary Myelo... | sunitinib malat... | 18 Years - | National Cancer Institute (NCI) | |
| Bortezomib and Vorinostat in Treating Patients With High-Risk Myelodysplastic Syndrome or Acute Myeloid Leukemia | NCT00818649 | Leukemia Myelodysplastic... | bortezomib vorinostat | 18 Years - | Masonic Cancer Center, University of Minnesota | |
| Selective Depletion of CD45RA+T Cells From Allogeneic Peripheral Blood Stem Cell Grafts for the Prevention of GVHD | NCT00914940 | Graft Versus Ho... Leukemia Myelodysplastic... | Fludarabine Pho... Tacrolimus Thiotepa Total-Body Irra... Magnetic Affini... Peripheral Bloo... Allogeneic Hema... T Cell-Depleted... | 14 Years - 55 Years | Fred Hutchinson Cancer Center | |
| Vaccine Therapy and GM-CSF in Treating Patients With Acute Myeloid Leukemia, Myelodysplastic Syndromes, Non-Small Cell Lung Cancer, or Mesothelioma | NCT00398138 | Leukemia Lung Cancer Malignant Mesot... Myelodysplastic... Primary Periton... | WT-1 analog pep... incomplete Freu... sargramostim polymerase chai... flow cytometry immunoenzyme te... | 18 Years - 120 Years | Memorial Sloan Kettering Cancer Center | |
| Azacitidine, Darbepoetin Alfa, and Erythropoietin and Filgastrim (G-CSF) in Treating Patients With Myelodysplastic Syndromes | NCT00398047 | Leukemia Myelodysplastic... | Azacitadine and... | - 120 Years | Wake Forest University Health Sciences | |
| Cediranib Maleate in Treating Patients With Relapsed, Refractory, or Untreated Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome | NCT00475150 | Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... de Novo Myelody... Previously Trea... Recurrent Adult... Secondary Acute... Secondary Myelo... Untreated Adult... | cediranib malea... laboratory biom... | 18 Years - | National Cancer Institute (NCI) | |
| Antithymocyte Globulin and Cyclosporine in Treating Patients With Myelodysplastic Syndrome | NCT00004208 | Myelodysplastic... | ATG + CSA Supportive care | 18 Years - | Swiss Group for Clinical Cancer Research | |
| Safety Study of Human Myeloid Progenitor Cells (CLT-008) After Cord Blood Transplant for Hematologic Malignancy | NCT00891137 | Leukemia Lymphoma Multiple Myelom... Plasma Cell Neo... Myelodysplastic... | human myeloid p... | 12 Years - 65 Years | Cellerant Therapeutics | |
| Detection of Residual Disease in Children Receiving Therapy for Acute Myeloid Leukemia or Myelodysplastic Syndrome | NCT00003790 | Leukemia Myelodysplastic... | polymerase chai... flow cytometry | - 21 Years | Children's Oncology Group | |
| VNP40101M and Cytarabine in Treating Patients With Hematologic Malignancies | NCT00070538 | Leukemia Myelodysplastic... | cytarabine laromustine | 18 Years - | National Cancer Institute (NCI) | |
| Azacitidine and Arsenic Trioxide in Treating Patients With Myelodysplastic Syndromes | NCT00234000 | Leukemia Myelodysplastic... | arsenic trioxid... azacitidine | 18 Years - | Jonsson Comprehensive Cancer Center | |
| Chemotherapy, Radiation Therapy, and Umbilical Cord Blood Transplantation in Treating Patients With Hematologic Cancer | NCT00003661 | Graft Versus Ho... Leukemia Lymphoma Myelodysplastic... Neuroblastoma | anti-thymocyte ... busulfan cyclosporine melphalan methylprednisol... umbilical cord ... radiation thera... | - 54 Years | Roswell Park Cancer Institute | |
| Vaccine Therapy and GM-CSF in Treating Patients With Acute Myeloid Leukemia, Myelodysplastic Syndromes, Non-Small Cell Lung Cancer, or Mesothelioma | NCT00398138 | Leukemia Lung Cancer Malignant Mesot... Myelodysplastic... Primary Periton... | WT-1 analog pep... incomplete Freu... sargramostim polymerase chai... flow cytometry immunoenzyme te... | 18 Years - 120 Years | Memorial Sloan Kettering Cancer Center | |
| 6-Hydroxymethylacylfulvene in Treating Patients With Refractory Myelodysplastic Syndrome, Acute Myeloid Leukemia, Acute Lymphocytic Leukemia, or Blastic Phase Chronic Myelogenous Leukemia | NCT00003997 | Leukemia Myelodysplastic... | irofulven | 18 Years - | National Cancer Institute (NCI) | |
| Lenalidomide and Azacitidine in Treating Patients With Advanced Myelodysplastic Syndromes | NCT00352001 | Leukemia Myelodysplastic... | azacitidine lenalidomide | 18 Years - 120 Years | Case Comprehensive Cancer Center | |
| Total-Body Irradiation, Tacrolimus, and Mycophenolate Mofetil Plus Bone Marrow Transplantation in Treating Patients With Hematologic Cancers | NCT00003572 | Leukemia Lymphoma Multiple Myelom... Myelodysplastic... | peripheral bloo... mycophenolate m... tacrolimus allogeneic bone... radiation thera... | 18 Years - 70 Years | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | |
| Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Myelodysplastic Syndrome | NCT00024050 | Leukemia Myelodysplastic... | busulfan cyclophosphamid... cyclosporine methotrexate allogeneic bone... peripheral bloo... | - 65 Years | Fred Hutchinson Cancer Center | |
| Umbilical Cord Blood Transplantation in Treating Patients With Hematologic Cancer or Other Hematologic or Metabolic Diseases | NCT00003662 | Graft Versus Ho... Leukemia Myelodysplastic... Thymic Carcinom... | anti-thymocyte ... busulfan cyclophosphamid... cyclosporine melphalan methylprednisol... umbilical cord ... radiation thera... | - | Roswell Park Cancer Institute | |
| Selective Depletion of CD45RA+T Cells From Allogeneic Peripheral Blood Stem Cell Grafts for the Prevention of GVHD | NCT00914940 | Graft Versus Ho... Leukemia Myelodysplastic... | Fludarabine Pho... Tacrolimus Thiotepa Total-Body Irra... Magnetic Affini... Peripheral Bloo... Allogeneic Hema... T Cell-Depleted... | 14 Years - 55 Years | Fred Hutchinson Cancer Center | |
| Paricalcitol in Treating Patients With Myelodysplastic Syndrome | NCT00064376 | Leukemia Myelodysplastic... | paricalcitol | 25 Years - 100 Years | Cedars-Sinai Medical Center | |
| Early Discharge and Outpatients Care in Patients With Myelodysplastic Syndrome or Acute Myeloid Leukemia Previously Treated With Intensive Chemotherapy | NCT01235572 | Adult Acute Meg... Adult Acute Min... Adult Acute Mon... Adult Acute Mon... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Erythrole... Adult Pure Eryt... Previously Trea... Recurrent Adult... | standard follow... medical chart r... quality-of-life... | 18 Years - 75 Years | Fred Hutchinson Cancer Center | |
| Belinostat in Treating Patients With Myelodysplastic Syndromes | NCT00357162 | de Novo Myelody... Previously Trea... Secondary Myelo... | belinostat | 18 Years - | National Cancer Institute (NCI) | |
| Removal of T Cells to Prevent Graft-Versus-Host Disease in Patients Undergoing Bone Marrow Transplantation | NCT00005641 | Chronic Myelopr... Graft Versus Ho... Leukemia Multiple Myelom... Myelodysplastic... | anti-thymocyte ... busulfan cyclophosphamid... cyclosporine leucovorin calc... methotrexate methylprednisol... allogeneic bone... in vitro-treate... radiation thera... | 15 Years - 60 Years | H. Lee Moffitt Cancer Center and Research Institute | |
| Cyclophosphamide and Busulfan Followed by Donor Stem Cell Transplant in Treating Patients With Myelofibrosis, Acute Myeloid Leukemia, or Myelodysplastic Syndrome | NCT00445744 | Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Childhood Acute... Childhood Myelo... de Novo Myelody... Essential Throm... Myelodysplastic... Polycythemia Ve... Previously Trea... Primary Myelofi... Recurrent Adult... Recurrent Child... Secondary Acute... Secondary Myelo... Secondary Myelo... Untreated Adult... Untreated Child... | cyclophosphamid... busulfan tacrolimus methotrexate cytogenetic ana... flow cytometry pharmacological... pharmacogenomic... peripheral bloo... allogeneic hema... | - 65 Years | Fred Hutchinson Cancer Center | |
| Empirical Versus Preemptive Antifungal Therapy | NCT01288378 | Fungal Infectio... Leukemia Myelodysplastic... | caspofungin ace... | 18 Years - | European Organisation for Research and Treatment of Cancer - EORTC | |
| Rebeccamycin Analog in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia, Myelodysplastic Syndrome, Acute Lymphoblastic Leukemia, or Chronic Myelogenous Leukemia | NCT00087204 | Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Blastic Phase C... Chronic Myelomo... de Novo Myelody... Previously Trea... Recurrent Adult... Recurrent Adult... Refractory Anem... Refractory Anem... Relapsing Chron... Secondary Acute... Secondary Myelo... | becatecarin laboratory biom... | 18 Years - | National Cancer Institute (NCI) | |
| Azacitidine and Lintuzumab in Treating Patients With Previously Untreated Myelodysplastic Syndromes | NCT00997243 | Leukemia Myelodysplastic... | lintuzumab 5-azacytidine | 18 Years - | Ohio State University Comprehensive Cancer Center | |
| Combination Chemotherapy With or Without Gemtuzumab Ozogamicin or Tipifarnib in Treating Patients With Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndromes | NCT00454480 | Leukemia Myelodysplastic... | alemtuzumab arsenic trioxid... azacitidine busulfan clofarabine cytarabine daunorubicin hy... fludarabine pho... gemtuzumab ozog... melphalan tipifarnib DNA methylation... cytogenetic ana... gene expression... mutation analys... diagnostic labo... immunologic tec... allogeneic hema... nonmyeloablativ... | - | National Cancer Institute (NCI) | |
| VNP40101M and Cytarabine in Treating Patients With Hematologic Malignancies | NCT00070538 | Leukemia Myelodysplastic... | cytarabine laromustine | 18 Years - | National Cancer Institute (NCI) | |
| Azacitidine and Arsenic Trioxide in Treating Patients With Myelodysplastic Syndromes or Chronic Myelomonocytic Leukemia | NCT00118196 | Leukemia Myelodysplastic... | arsenic trioxid... azacitidine | 18 Years - 120 Years | Medical University of South Carolina | |
| Total-Body Irradiation, Thiotepa, and Fludarabine in Treating Young Patients Who Are Undergoing a Donor Stem Cell Transplant for Hematologic Cancer | NCT00112567 | Leukemia Myelodysplastic... | fludarabine pho... thiotepa peripheral bloo... radiation thera... | - 20 Years | Fred Hutchinson Cancer Center | |
| Iodine I 131 Monoclonal Antibody BC8, Fludarabine Phosphate, Total Body Irradiation, and Donor Stem Cell Transplant Followed by Cyclosporine and Mycophenolate Mofetil in Treating Patients With Advanced Acute Myeloid Leukemia or Myelodysplastic Syndrome | NCT00119366 | Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Childhood Myelo... Chronic Myelomo... Previously Trea... Recurrent Adult... Recurrent Child... Refractory Anem... Refractory Anem... Refractory Anem... Refractory Cyto... Secondary Acute... Secondary Myelo... | iodine I 131 mo... fludarabine pho... total-body irra... allogeneic hema... peripheral bloo... cyclosporine mycophenolate m... laboratory biom... | 16 Years - 50 Years | Fred Hutchinson Cancer Center | |
| S9920 Busulfan Compared With Cyclophosphamide in Patients Undergoing Total-Body Irradiation Plus Peripheral Stem Cell Transplantation for Advanced Myelodysplastic Syndrome or Related Acute Myeloid Leukemia | NCT00005866 | Leukemia Myelodysplastic... | busulfan cyclophosphamid... cyclosporine methotrexate allogeneic bone... radiation thera... | 16 Years - 55 Years | SWOG Cancer Research Network | |
| Donor Stem Cell Transplant in Treating Older or Frail Patients With Hematologic Cancer | NCT00296023 | Chronic Myelopr... Leukemia Lymphoma Multiple Myelom... Myelodysplastic... | anti-thymocyte ... filgrastim therapeutic all... busulfan fludarabine pho... methotrexate tacrolimus nonmyeloablativ... peripheral bloo... | 18 Years - 75 Years | University of California, San Francisco | |
| Cyclophosphamide Plus T-Cell Transplantation for Patients With Hematologic Malignancies | NCT00356928 | Leukemia Myelodysplastic... | Cyclophosphamid... Donor T cells | 18 Years - 120 Years | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | |
| Combination Chemotherapy With or Without Peripheral Stem Cell Transplantation in Treating Patients With Myelodysplastic Syndrome or Acute Myelogenous Leukemia | NCT00002926 | Leukemia Myelodysplastic... | cytarabine etoposide idarubicin allogeneic bone... peripheral bloo... | 16 Years - 60 Years | National Cancer Institute (NCI) | |
| Combination Chemotherapy With or Without Bone Marrow Transplantation in Treating Children With Acute Myeloid Leukemia | NCT00003436 | Leukemia Myelodysplastic... | amsacrine asparaginase cytarabine daunorubicin hy... etoposide methotrexate mitoxantrone hy... therapeutic hyd... allogeneic bone... | - 15 Years | National Cancer Institute (NCI) | |
| Chemotherapy and Total-Body Irradiation Followed by Donor Umbilical Cord Blood Transplant, Cyclosporine, and Mycophenolate Mofetil in Treating Patients With Hematologic Cancer | NCT00290641 | Chronic Myelopr... Leukemia Lymphoma Myelodysplastic... | filgrastim graft-versus-tu... cyclophosphamid... cyclosporine fludarabine pho... mycophenolate m... umbilical cord ... radiation thera... | - 45 Years | Masonic Cancer Center, University of Minnesota | |
| Vaccine Therapy in Treating Patients With Myelodysplastic Syndrome | NCT00003959 | Leukemia Myelodysplastic... | ras peptide can... sargramostim | 17 Years - | Memorial Sloan Kettering Cancer Center | |
| Combination Chemotherapy, Donor Stem Cell Transplant, Tacrolimus, Mycophenolate Mofetil, and Cyclophosphamide in Treating Patients With Hematologic Cancer | NCT00782379 | Leukemia Lymphoma Myelodysplastic... | busulfan cyclophosphamid... fludarabine pho... mycophenolate m... tacrolimus allogeneic hema... peripheral bloo... | 18 Years - 60 Years | Northside Hospital, Inc. | |
| Chemotherapy, Radiation Therapy, and Umbilical Cord Blood Transplantation in Treating Patients With Hematologic Cancer | NCT00003661 | Graft Versus Ho... Leukemia Lymphoma Myelodysplastic... Neuroblastoma | anti-thymocyte ... busulfan cyclosporine melphalan methylprednisol... umbilical cord ... radiation thera... | - 54 Years | Roswell Park Cancer Institute | |
| Donor Peripheral Stem Cell Transplant and Donor Natural Killer Cell Transplant After Total-Body Irradiation, Thiotepa, Fludarabine, and Muromonab-CD3 in Treating Patients With Leukemia or Other Blood Diseases | NCT00450983 | Graft Versus Ho... Leukemia Myelodysplastic... | muromonab-CD3 natural killer ... fludarabine pho... methotrexate thiotepa gene expression... flow cytometry immunologic tec... allogeneic hema... in vitro-treate... total-body irra... | - 45 Years | Fred Hutchinson Cancer Center | |
| Cediranib Maleate in Treating Patients With Relapsed, Refractory, or Untreated Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome | NCT00475150 | Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... de Novo Myelody... Previously Trea... Recurrent Adult... Secondary Acute... Secondary Myelo... Untreated Adult... | cediranib malea... laboratory biom... | 18 Years - | National Cancer Institute (NCI) | |
| Combination Chemotherapy With or Without Bone Marrow Transplantation in Treating Children With Acute Myelogenous Leukemia or Myelodysplastic Syndrome | NCT00002798 | Childhood Acute... Childhood Acute... Childhood Acute... Childhood Acute... Childhood Acute... Childhood Acute... Childhood Acute... Childhood Myelo... Chronic Myelomo... de Novo Myelody... Refractory Anem... Refractory Anem... Refractory Anem... Refractory Anem... Secondary Myelo... Untreated Child... | asparaginase daunorubicin hy... fludarabine pho... therapeutic hyd... allogeneic bone... 3-dimensional c... filgrastim cytarabine idarubicin dexamethasone thioguanine etoposide methotrexate cyclophosphamid... aldesleukin busulfan | - 21 Years | National Cancer Institute (NCI) | |
| Studying Blood Samples in Young Patients With Cytopenia After a Donor Stem Cell Transplant | NCT00898118 | Leukemia Myelodysplastic... | polymerase chai... flow cytometry laboratory biom... allogeneic hema... | - 17 Years | National Cancer Institute (NCI) | |
| Sorafenib and Low Dose Cytarabine in Older Patients With Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome | NCT00516828 | Leukemia Myelodysplastic... | cytarabine | 60 Years - | Canadian Cancer Trials Group | |
| Tipifarnib in Treating Patients With Advanced Hematologic Cancer | NCT00005967 | Chronic Myelopr... Leukemia Lymphoma Multiple Myelom... Myelodysplastic... | tipifarnib | 18 Years - | National Cancer Institute (NCI) | |
| DT388IL3 Fusion Protein in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndromes | NCT00397579 | Leukemia Myelodysplastic... Blastic Plasmac... | DT388IL3 | 18 Years - | University of Texas Southwestern Medical Center | |
| Azacitidine Plus Amifostine in Treating Patients With Myelodysplastic Syndrome | NCT00005598 | Myelodysplastic... | amifostine trih... azacitidine | 18 Years - | University of Michigan Rogel Cancer Center | |
| Quality of Life of Adult Cancer Survivors Who Have Undergone a Previous Bone Marrow or Peripheral Stem Cell Transplant for a Childhood Hematologic Cancer | NCT00126477 | Leukemia Lymphoma Myelodysplastic... Quality of Life | cognitive asses... management of t... psychosocial as... quality-of-life... | 18 Years - | Fred Hutchinson Cancer Center | |
| Lenalidomide and Azacitidine in Treating Patients With Advanced Myelodysplastic Syndromes | NCT00352001 | Leukemia Myelodysplastic... | azacitidine lenalidomide | 18 Years - 120 Years | Case Comprehensive Cancer Center | |
| Monoclonal Antibody Therapy in Treating Patients With Primary Myelodysplastic Syndrome | NCT00003984 | Myelodysplastic... | lintuzumab | 18 Years - | European Organisation for Research and Treatment of Cancer - EORTC | |
| Early Discharge and Outpatients Care in Patients With Myelodysplastic Syndrome or Acute Myeloid Leukemia Previously Treated With Intensive Chemotherapy | NCT01235572 | Adult Acute Meg... Adult Acute Min... Adult Acute Mon... Adult Acute Mon... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Erythrole... Adult Pure Eryt... Previously Trea... Recurrent Adult... | standard follow... medical chart r... quality-of-life... | 18 Years - 75 Years | Fred Hutchinson Cancer Center | |
| Helical Tomotherapy, Fludarabine Phosphate, and Melphalan Followed By Allo-HSCT in Hematological Malignancies | NCT00544466 | Leukemia Myelodysplastic... | fludarabine pho... melphalan allogeneic hema... intensity-modul... | 7 Years - | City of Hope Medical Center | |
| Combination Chemotherapy in Treating Patients With Myelodysplastic Syndrome | NCT00003827 | Leukemia Myelodysplastic... | amifostine trih... cytarabine topotecan hydro... | 16 Years - | National Cancer Institute (NCI) | |
| Donor Bone Marrow Transplant With or Without G-CSF in Treating Young Patients With Hematologic Cancer or Other Diseases | NCT00450450 | Childhood Acute... Childhood Acute... Childhood Chron... Childhood Myelo... Chronic Phase C... de Novo Myelody... Juvenile Myelom... Previously Trea... Recurrent Child... Secondary Myelo... | allogeneic bone... laboratory biom... filgrastim | - 21 Years | Children's Oncology Group | |
| Rebeccamycin Analog in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia, Myelodysplastic Syndrome, Acute Lymphoblastic Leukemia, or Chronic Myelogenous Leukemia | NCT00087204 | Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Blastic Phase C... Chronic Myelomo... de Novo Myelody... Previously Trea... Recurrent Adult... Recurrent Adult... Refractory Anem... Refractory Anem... Relapsing Chron... Secondary Acute... Secondary Myelo... | becatecarin laboratory biom... | 18 Years - | National Cancer Institute (NCI) | |
| Laboratory-Treated Lymphocyte Infusion After Haploidentical Donor Stem Cell Transplant | NCT00376480 | Leukemia Myelodysplastic... | anti-thymocyte ... peripheral bloo... fludarabine pho... methylprednisol... thiotepa allogeneic hema... in vitro-treate... total-body irra... | - 50 Years | Dana-Farber Cancer Institute | |
| Donor Stem Cell Transplant in Treating Young Patients With Myelodysplastic Syndrome, Leukemia, Bone Marrow Failure Syndrome, or Severe Immunodeficiency Disease | NCT00295971 | Congenital Ameg... Leukemia Myelodysplastic... Severe Congenit... | anti-thymocyte ... therapeutic all... fludarabine pho... thiotepa allogeneic bone... allogeneic hema... in vitro-treate... total-body irra... | 1 Year - 17 Years | University of California, San Francisco | |
| Busulfan, Etoposide, and Total-Body Irradiation in Treating Patients Undergoing Donor Stem Cell or Bone Marrow Transplant for Advanced Hematologic Cancer | NCT00534430 | Leukemia Myelodysplastic... | busulfan cyclosporine etoposide mycophenolate m... allogeneic bone... allogeneic hema... peripheral bloo... total-body irra... | 16 Years - 50 Years | City of Hope Medical Center | |
| Identification of de Novo Fanconi Anemia in Younger Patients With Newly Diagnosed Acute Myeloid Leukemia | NCT01146210 | Childhood Acute... Childhood Acute... Childhood Acute... Childhood Acute... Childhood Acute... Childhood Acute... Childhood Acute... Childhood Acute... Childhood Myelo... Chronic Myelomo... de Novo Myelody... Fanconi Anemia Refractory Anem... Refractory Anem... Refractory Anem... Refractory Anem... Secondary Myelo... Untreated Child... | laboratory biom... | - 21 Years | Children's Oncology Group | |
| Laboratory-Treated Lymphocyte Infusion After Haploidentical Donor Stem Cell Transplant | NCT00376480 | Leukemia Myelodysplastic... | anti-thymocyte ... peripheral bloo... fludarabine pho... methylprednisol... thiotepa allogeneic hema... in vitro-treate... total-body irra... | - 50 Years | Dana-Farber Cancer Institute | |
| Cellular Adoptive Immunotherapy in Treating Patients With Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, or Myelodysplastic Syndromes That Relapsed After Donor Stem Cell Transplant | NCT00107354 | Leukemia Myelodysplastic... | aldesleukin therapeutic all... therapeutic aut... cytarabine etoposide mitoxantrone hy... allogeneic bone... peripheral bloo... | 14 Years - | Fred Hutchinson Cancer Center | |
| Cediranib Maleate in Treating Patients With Relapsed, Refractory, or Untreated Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome | NCT00475150 | Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... de Novo Myelody... Previously Trea... Recurrent Adult... Secondary Acute... Secondary Myelo... Untreated Adult... | cediranib malea... laboratory biom... | 18 Years - | National Cancer Institute (NCI) | |
| Donor T Cells in Treating Patients With High-Risk Hematologic Cancer Undergoing Donor Peripheral Blood Stem Cell Transplant | NCT00725062 | Graft Versus Ho... Leukemia Lymphoma Multiple Myelom... Myelodysplastic... | CD4+CD25+ regul... allogeneic hema... | 18 Years - 70 Years | Masonic Cancer Center, University of Minnesota | |
| Amifostine in Treating Patients With Myelodysplastic Syndrome | NCT00003048 | Myelodysplastic... | Amifostine Trih... | 18 Years - | M.D. Anderson Cancer Center | |
| Vaccine Therapy and GM-CSF in Treating Patients With Acute Myeloid Leukemia, Myelodysplastic Syndromes, Non-Small Cell Lung Cancer, or Mesothelioma | NCT00398138 | Leukemia Lung Cancer Malignant Mesot... Myelodysplastic... Primary Periton... | WT-1 analog pep... incomplete Freu... sargramostim polymerase chai... flow cytometry immunoenzyme te... | 18 Years - 120 Years | Memorial Sloan Kettering Cancer Center | |
| Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Myelodysplastic Syndrome | NCT00024050 | Leukemia Myelodysplastic... | busulfan cyclophosphamid... cyclosporine methotrexate allogeneic bone... peripheral bloo... | - 65 Years | Fred Hutchinson Cancer Center | |
| Radiolabeled Monoclonal Antibody Therapy, Fludarabine Phosphate, and Low-Dose Total-Body Irradiation Followed by Donor Stem Cell Transplant and Immunosuppression Therapy in Treating Older Patients With Advanced Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndromes | NCT00008177 | Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Chronic Myelomo... de Novo Myelody... Previously Trea... Recurrent Adult... Refractory Anem... Refractory Anem... Refractory Anem... Refractory Cyto... Secondary Myelo... Untreated Adult... | iodine I 131 mo... total-body irra... allogeneic hema... peripheral bloo... fludarabine pho... cyclosporine mycophenolate m... laboratory biom... | 50 Years - | Fred Hutchinson Cancer Center | |
| S0020 Immunosuppressive Therapy in Treating Patients With Myelodysplastic Syndrome | NCT00016419 | Leukemia Myelodysplastic... | anti-thymocyte ... cyclosporine | 15 Years - | SWOG Cancer Research Network | |
| Idarubicin, Cytarabine, and Tipifarnib in Treating Patients With Newly Diagnosed Myelodysplastic Syndromes or Acute Myeloid Leukemia | NCT00096122 | Adult Acute Bas... Adult Acute Eos... Adult Acute Meg... Adult Acute Min... Adult Acute Mon... Adult Acute Mon... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Erythrole... Adult Pure Eryt... Childhood Myelo... Chronic Myelomo... de Novo Myelody... Refractory Anem... Refractory Anem... Secondary Acute... Secondary Myelo... Untreated Adult... | cytarabine idarubicin tipifarnib | 15 Years - 70 Years | National Cancer Institute (NCI) | |
| Total-Body Irradiation, Fludarabine, and Alemtuzumab Followed By Stem Cell Transplant in Treating Patients With Myeloproliferative Disorder, MS, AML, or CML | NCT00069992 | Chronic Myelopr... Leukemia Myelodysplastic... | Total Body Irra... Fludarabine Campath 1H | - | Baylor College of Medicine | |
| Tosedostat in Combination With Cytarabine or Decitabine in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome | NCT01567059 | Acute Myeloid L... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... de Novo Myelody... Previously Trea... Secondary Acute... Secondary Myelo... Untreated Adult... | tosedostat cytarabine decitabine | 18 Years - | Fred Hutchinson Cancer Center | |
| Amifostine & High-Dose Combination Chemotherapy in Treating Patients With Acute ML or CML | NCT00003407 | Drug/Agent Toxi... Leukemia Myelodysplastic... Neutropenia | amifostine trih... cytarabine mitoxantrone hy... | 18 Years - 120 Years | Rush University Medical Center |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
